Comparative Pharmacology
Head-to-head clinical analysis: CEREZYME versus XENPOZYME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEREZYME versus XENPOZYME.
CEREZYME vs XENPOZYME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imiglucerase is a recombinant form of the lysosomal enzyme β-glucocerebrosidase, which catalyzes the hydrolysis of glucocerebroside to glucose and ceramide. It replaces deficient endogenous enzyme in patients with Gaucher disease, reducing accumulated glucocerebroside in macrophages.
XENPOZYME (olipudro alfa) is a recombinant human acid alpha-glucosidase (GAA) enzyme replacement therapy. It hydrolyzes lysosomal glycogen by cleaving α-1,4 and α-1,6 glycosidic linkages, thereby reducing glycogen accumulation in tissues, particularly skeletal muscle.
60 units/kg intravenously every 2 weeks; infusion rate not to exceed 1 mg/min (equivalent to 2 units/kg/min).
40 mg intravenously over 60 minutes every 2 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 3.6–10.4 hours (median 5.8 hours) after IV infusion. Clinical context: supports weekly or biweekly dosing (30–60 IU/kg every 2 weeks).
The terminal elimination half-life is approximately 6-9 hours. This relatively short half-life supports weekly intravenous administration to maintain therapeutic enzyme levels.
Primarily metabolized via proteolysis into small peptides and amino acids; renal excretion of metabolites is minimal (<5% unchanged). Biliary/fecal excretion not quantified due to protein nature.
Xenpozyme (olipudro alfa) is a recombinant lysosomal acid lipase (LAL) enzyme replacement therapy. As a protein, it undergoes catabolism via peptide hydrolysis into amino acids, which are reused or excreted. Renal excretion of intact drug is negligible. No specific studies on biliary/fecal elimination have been published; however, catabolic products are primarily excreted renally as amino acids.
Category C
Category C
Enzyme replacement therapy
Enzyme replacement therapy